Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/162640
Title: Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Authors: Chuah, Samuel
Lee, Joycelyn
Song, Yuan
Kim, Hyung-Don
Wasser, Martin
Kaya, Neslihan A.
Bang, Kyunghye
Lee, Yong Joon
Jeon, Seung Hyuck
Suthen, Sheena
A'Azman, Shamirah
Gien, Gerald
Lim, Chun Jye
Chua, Camillus
Sharifah Nur Hazirah
Lee, Hong Kai
Lim, Jia Qi
Lim, Tony K. H.
Yeong, Joe
Chen, Jinmiao
Shin, Eui-Cheol
Albani, Salvatore
Zhai, Weiwei
Yoo, Changhoon
Liu, Haiyan
Choo, Su Pin
Tai, David
Chew, Valerie
Keywords: Science::Biological sciences
Issue Date: 2022
Source: Chuah, S., Lee, J., Song, Y., Kim, H., Wasser, M., Kaya, N. A., Bang, K., Lee, Y. J., Jeon, S. H., Suthen, S., A'Azman, S., Gien, G., Lim, C. J., Chua, C., Sharifah Nur Hazirah, Lee, H. K., Lim, J. Q., Lim, T. K. H., Yeong, J., ...Chew, V. (2022). Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 77(3), 683-694. https://dx.doi.org/10.1016/j.jhep.2022.03.039
Project: NMRC/OFLCG/003/2018
NMRC/TCR/015-NCC/2016
NMRC/CSA-SI/0013/2017
NMRC/CSA-SI/0018/2017
NMRC/STaR/020/2013
Journal: Journal of Hepatology
Abstract: Background & Aims: While immune checkpoint blockade (ICB) has shown promise in patients with hepatocellular carcinoma (HCC), it is associated with modest response rates and immune-related adverse events (irAEs) are common. In this study, we aimed to decipher immune trajectories and mechanisms of response and/or irAEs in patients with HCC receiving anti-programmed cell death 1 (anti-PD-1) therapy. Methods: Pre- and on-treatment peripheral blood samples (n = 60) obtained from 32 patients with HCC (Singapore cohort) were analysed by cytometry by time-of-flight and single-cell RNA sequencing, with flow cytometric validation in an independent Korean cohort (n = 29). Mechanistic validation was conducted by bulk RNA sequencing of 20 pre- and on-treatment tumour biopsies and using a murine HCC model treated with different immunotherapeutic combinations. Results: Single-cell analyses identified CXCR3+ CD8+ effector memory T (TEM) cells and CD11c+ antigen-presenting cells (APC) as associated with response (p = 0.0004 and 0.0255, respectively), progression-free survival (p = 0.00079 and 0.0015, respectively), and irAEs (p = 0.0034 and 0.0125, respectively) in anti-PD-1-treated patients with HCC. Type-1 conventional dendritic cells were identified as the specific APC associated with response, while 2 immunosuppressive CD14+ myeloid clusters were linked to reduced irAEs. Further analyses of CXCR3+ CD8+ TEM cells showed cell-cell interactions specific to response vs. irAEs, from which the anti-PD-1 and anti-TNFR2 combination was harnessed to uncouple these effects, resulting in enhanced response without increased irAEs in a murine HCC model. Conclusions: This study identifies early predictors of clinical response to anti-PD-1 ICB in patients with HCC and offers mechanistic insights into the immune trajectories of these immune subsets at the interface between response and toxicity. We also propose a new combination immunotherapy for HCC to enhance response without exacerbating irAEs.
URI: https://hdl.handle.net/10356/162640
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2022.03.039
Rights: © 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
PIIS0168827822002331.pdf3.23 MBAdobe PDFView/Open

SCOPUSTM   
Citations 50

6
Updated on Nov 26, 2022

Page view(s)

16
Updated on Nov 26, 2022

Download(s)

3
Updated on Nov 26, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.